{"id":3844,"date":"2015-04-29T17:06:06","date_gmt":"2015-04-29T15:06:06","guid":{"rendered":"http:\/\/news.embl.de\/?p=3844"},"modified":"2024-11-14T16:26:11","modified_gmt":"2024-11-14T15:26:11","slug":"1504-cortese","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/","title":{"rendered":"Inside industry: Part I"},"content":{"rendered":"\n<h2 class=\"p1 wp-block-heading\">Innovation in vaccine development<\/h2>\n\n\n\n<h3 class=\"p1 wp-block-heading\"><span class=\"s1\">By Stefano De Renzis<\/span><\/h3>\n\n\n\n<p class=\"p1\"><b>The Ebola vaccine \u2013 currently being tested \u2013 is based on your work with Okairos, what is special about it?<br \/><\/b>Traditional vaccines &#8216;train&#8217; the B lymphocytes into recognising deactivated parts of the pathogen, so they can destroy it more effectively should the body be infected. Unfortunately, this does not always ensure effective protection. I founded the start-up Okairos in 2007 to develop new genetic vaccines, which trigger both T- and B-lymphocyte activation. We started working on the Ebola virus well before the last outbreak in West Africa because it was one of the most dangerous and untreatable pathogens: succeeding with it would be a fantastic proof of concept for our technology.<\/p>\n\n\n\n<blockquote class=\"vf-blockquote\"><p class=\"p1\">We used chimpanzees&#8217; adenoviruses as a &#8216;Trojan horses&#8217; in which we inserted Ebola-specific proteins.<\/p><\/blockquote>\n\n\n\n<p class=\"p2\">Unlike the human adenoviruses which are rapidly inactivated by our immune system \u2013 we have all been exposed to adenoviral infection \u2013, those of chimpanzees are not recognised by our immune system and trigger a strong response, both from the T- and the B-lymphocytes. We therefore used chimpanzees&#8217; adenoviruses as a &#8216;Trojan horses&#8217; in which we inserted Ebola-specific proteins. We proved the efficacy of our T-cell based vaccines in these animal models, and sold Okairos to GlaxoSmithKline (GSK) so it could be further developed. Now our Ebola vaccine is in a phase III clinical trial involving 30 000 individuals.<\/p>\n\n\n\n<figure class=\"vf-figure wp-block-image alignnone wp-image-3847 size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"620\" height=\"380\" class=\"vf-figure__image\" src=\"https:\/\/news.embl.de\/wp-content\/uploads\/2015\/04\/Ebola-WEB.jpg\" alt=\"The Ebola virus is one of the most dangerous and untreatable pathogens. IMAGE: Frederick Murphy \/ CDC Handout\" class=\"wp-image-3847\" srcset=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/Ebola-WEB.jpg 620w, https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/Ebola-WEB-300x184.jpg 300w\" sizes=\"auto, (max-width: 620px) 100vw, 620px\" \/><figcaption class=\"vf-figure__caption\">The Ebola virus is one of the most dangerous and untreatable pathogens. IMAGE: <a href=\"'http:\/\/phil.cdc.gov\/phil\/details_linked.asp?pid=10815\/&quot;\">Frederick Murphy\/CDC<\/a><\/figcaption><\/figure>\n\n\n\n<p class=\"p1\"><b>What made you move from academia to the private sector?<br \/><\/b>I sailed from academia to industry and then biotech: each move driven by restlessness, curiosity and a lot of optimism. I\u2019ve always felt curious about my research topics, obviously, but also about how I could apply them, maybe a consequence of my medical training\u2026 All of these steps were a jump into the dark.<\/p>\n\n\n\n<p class=\"p2\">After EMBL, I directed the Integrated Research Biotech Model (IRBM) in Rome where we developed several drugs that are now on the market. This was a great job, so leaving it to start something new like Okairos was risky, but also extremely exciting. In ancient Greek, Okairos stands for \u201cright timing\u201d and I felt that it was the right time for me to do it. Now, I am again in a position to start a new company, this time dedicated to new level vectors to provide a cure for diseases such as cancer.<\/p>\n\n\n\n<blockquote class=\"vf-blockquote\"><p class=\"p2\">I sailed from academia to industry and then biotech: each move driven by restlessness, curiosity and a lot of optimism.<\/p><\/blockquote>\n\n\n\n<p class=\"p1\"><b>You\u2019ve had a very diverse and fulfilling career, what advice would you give young EMBLers?<br \/><\/b>In 1981 I founded the Gene Expression Programme (now the Genome Biology Unit) at EMBL, so I was able to develop managerial skills in addition to my scientific expertise. This combination proved very successful during my career. EMBL in general has a very strong reputation \u2013 which goes far in industry \u2013 and offers many opportunities to its scientists and students. I would advise all EMBLers to make the most of this while working in such an inspiring and invigorating environment.<\/p>\n\n\n\n<p class=\"p1\"><b>What is your fondest memory of your time at EMBL?<br \/><\/b>I fitted well into the EMBL culture as a convert and proponent of the \u201cEuropean mission\u201d, so it was an interesting and intense time for me. I attracted a lot of Italians: we were all in the same corridor, which apparently had the permanent aroma of espresso. The team spirit was very strong: we even trained together at my home to win the prestigious EMBL beer competition against the British and the Germans!<\/p>\n\n\n<hr class=\"vf-divider\"\/>\n\n\n<p class=\"p1\"><a href=\"http:\/\/news.embl.de\/alumni\/1504-inside-industry\/\">Inside industry: Part II &gt;<\/a> A<span class=\"s1\">lumni in senior positions at the companies attracting the largest numbers of alumni share why they made the move, the challenges and highlights facing them, and EMBL\u2019s continuing role in their career.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Career insights from Riccardo Cortese, whose start-up is developing an Ebola vaccine candidate.<\/p>\n","protected":false},"author":16,"featured_media":3845,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5,3],"tags":[80,59,362,42,155,71],"embl_taxonomy":[],"class_list":["post-3844","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alumni","category-lab-matters","tag-alumni","tag-careers","tag-de-renzis","tag-genomics","tag-gsk","tag-industry"],"acf":{"article_intro":"<p>Riccardo Cortese, former head of the Genome Biology Unit, talks about the Ebola vaccine candidate developed by his start-up, and reflects on his successful career in research and industry.<\/p>\n","related_links":[{"link_description":"Okairos, acquired by GlaxoSmithKlein in 2013","link_url":"http:\/\/www.okairos.com\/e\/index.php"},{"link_description":"EMBL Genome Biology unit","link_url":"http:\/\/www.embl.de\/research\/units\/genome_biology"}],"article_sources":false,"vf_locked":false,"featured":false,"color":"#007B53"},"embl_taxonomy_terms":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Inside industry: Part I | EMBL<\/title>\n<meta name=\"description\" content=\"Career insights from Riccardo Cortese, whose start-up is developing an Ebola vaccine candidate.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inside industry: Part I | EMBL\" \/>\n<meta property=\"og:description\" content=\"Career insights from Riccardo Cortese, whose start-up is developing an Ebola vaccine candidate.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-04-29T15:06:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-14T15:26:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/33_Ricardo-Cortese-WEB.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"425\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Guest author(s)\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Guest author(s)\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/\"},\"author\":{\"name\":\"Guest author(s)\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/b4d9366b2ebe691c4015c64c3619205b\"},\"headline\":\"Inside industry: Part I\",\"datePublished\":\"2015-04-29T15:06:06+00:00\",\"dateModified\":\"2024-11-14T15:26:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/\"},\"wordCount\":638,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/33_Ricardo-Cortese-WEB.jpg\",\"keywords\":[\"alumni\",\"careers\",\"de renzis\",\"genomics\",\"gsk\",\"industry\"],\"articleSection\":[\"Alumni\",\"Lab Matters\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/\",\"url\":\"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/\",\"name\":\"Inside industry: Part I | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/33_Ricardo-Cortese-WEB.jpg\",\"datePublished\":\"2015-04-29T15:06:06+00:00\",\"dateModified\":\"2024-11-14T15:26:11+00:00\",\"description\":\"Career insights from Riccardo Cortese, whose start-up is developing an Ebola vaccine candidate.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/33_Ricardo-Cortese-WEB.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/33_Ricardo-Cortese-WEB.jpg\",\"width\":620,\"height\":425,\"caption\":\"Riccardo Cortese, former head of the Genome Biology Unit. PHOTO: EMBL Photolab\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/b4d9366b2ebe691c4015c64c3619205b\",\"name\":\"Guest author(s)\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/300b9a1d66050ae03eaeb99869c6ebb30f5184b9468e92a2b3e7d28bc9cf742d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/300b9a1d66050ae03eaeb99869c6ebb30f5184b9468e92a2b3e7d28bc9cf742d?s=96&d=mm&r=g\",\"caption\":\"Guest author(s)\"},\"description\":\"Guest author(s)\",\"url\":\"https:\/\/www.embl.org\/news\/author\/guest-author\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inside industry: Part I | EMBL","description":"Career insights from Riccardo Cortese, whose start-up is developing an Ebola vaccine candidate.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/","og_locale":"en_US","og_type":"article","og_title":"Inside industry: Part I | EMBL","og_description":"Career insights from Riccardo Cortese, whose start-up is developing an Ebola vaccine candidate.","og_url":"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2015-04-29T15:06:06+00:00","article_modified_time":"2024-11-14T15:26:11+00:00","og_image":[{"width":620,"height":425,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/33_Ricardo-Cortese-WEB.jpg","type":"image\/jpeg"}],"author":"Guest author(s)","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Guest author(s)","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/"},"author":{"name":"Guest author(s)","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/b4d9366b2ebe691c4015c64c3619205b"},"headline":"Inside industry: Part I","datePublished":"2015-04-29T15:06:06+00:00","dateModified":"2024-11-14T15:26:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/"},"wordCount":638,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/33_Ricardo-Cortese-WEB.jpg","keywords":["alumni","careers","de renzis","genomics","gsk","industry"],"articleSection":["Alumni","Lab Matters"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/","url":"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/","name":"Inside industry: Part I | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/33_Ricardo-Cortese-WEB.jpg","datePublished":"2015-04-29T15:06:06+00:00","dateModified":"2024-11-14T15:26:11+00:00","description":"Career insights from Riccardo Cortese, whose start-up is developing an Ebola vaccine candidate.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/alumni\/1504-cortese\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/33_Ricardo-Cortese-WEB.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/33_Ricardo-Cortese-WEB.jpg","width":620,"height":425,"caption":"Riccardo Cortese, former head of the Genome Biology Unit. PHOTO: EMBL Photolab"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/b4d9366b2ebe691c4015c64c3619205b","name":"Guest author(s)","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/300b9a1d66050ae03eaeb99869c6ebb30f5184b9468e92a2b3e7d28bc9cf742d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/300b9a1d66050ae03eaeb99869c6ebb30f5184b9468e92a2b3e7d28bc9cf742d?s=96&d=mm&r=g","caption":"Guest author(s)"},"description":"Guest author(s)","url":"https:\/\/www.embl.org\/news\/author\/guest-author\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/33_Ricardo-Cortese-WEB.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/04\/33_Ricardo-Cortese-WEB.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/3844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=3844"}],"version-history":[{"count":18,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/3844\/revisions"}],"predecessor-version":[{"id":20699,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/3844\/revisions\/20699"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/3845"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=3844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=3844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=3844"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=3844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}